Summary & Overview
HCPCS P9037: Platelets, Pheresis, Leukocytes Reduced, Irradiated, Each Unit
HCPCS Level II code P9037 represents a specialized plateletpheresis unit prepared as leukocyte-reduced and irradiated for transfusion. This designation identifies a blood product intended to lower the risk of febrile nonhemolytic transfusion reactions, alloimmunization, and transfusion-associated graft-versus-host disease in at-risk patients. Nationally, accurate coding of prepared blood components influences billing consistency, clinical inventory management, and quality reporting across hospital transfusion services and outpatient infusion centers.
Key payers in the analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for P9037, where the service is typically delivered, and which payers commonly reimburse for this type of prepared platelet unit. The publication outlines benchmark considerations for claims processing, notes common modifier usage where available, and highlights operational implications for blood banks and transfusion services.
Content is presented to support coding accuracy and administrative clarity: definitions of the product represented by P9037, payer coverage scope, and the types of benchmarks and policy updates readers should expect to consult when managing billing and clinical workflows involving specialized platelet units.
Billing Code Overview
HCPCS Level II code P9037 describes platelets, pheresis, leukocytes reduced, irradiated, each unit. The service type is blood product transfusion — specialized platelet unit preparation, reflecting plateletpheresis units that have undergone both leukocyte reduction and irradiation to reduce white cell content and mitigate transfusion-associated risks.
Typical site of service for P9037 is hospital-based transfusion services and outpatient infusion centers where blood component therapy is administered and monitored. Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient scenario involves an adult hospitalized patient with thrombocytopenia or platelet dysfunction requiring platelet transfusion for hemostatic support. For example, a 58-year-old chemotherapy-treated patient with acute myeloid leukemia develops platelet count <10,000/µL with mucosal bleeding and requires transfusion. The transfusion service issues apheresis platelets that have been leukocyte reduced and irradiated to reduce risk of febrile nonhemolytic transfusion reactions, alloimmunization, and transfusion-associated graft-versus-host disease. The clinical workflow includes physician order entry specifying product attributes (apheresis, leukoreduced, irradiated), blood bank verification of patient identifiers and crossmatch requirements, issuance of unit(s) labeled as P9037, bedside identity and vital sign monitoring during transfusion, and post-transfusion documentation of volume transfused and any adverse reactions. Typical site of service is inpatient hospital (acute care) or hospital outpatient transfusion center; occasionally performed in ambulatory oncology infusion centers with transfusion capability.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Unspecified | Rarely used; not typically appended for blood products |